Manufacturing

Articles

Curia and the US government have entered into a cooperative agreement to expand fill/finish capability for injectable medicines.

Curia Enters Cooperative Agreement with US Government to Expand Sterile Fill/Finish Capability

Moderna and Thermo Fisher Scientific have formed a collaboration to leverage dedicated commercial fill/finish manufacturing capacity in the US for mRNA vaccines and therapies.

Moderna and Thermo Fisher Scientific Form Long-Term Strategic Manufacturing Collaboration

Eli Lilly and Company is investing $1 billion to establish a new manufacturing site in Concord, NC, to manufacture parenteral products and devices.

Lilly to Invest $1 Billion to Build New Parenteral Manufacturing Facility in North Carolina

Fareva plans to use blow-fill-seal equipment and ApiJect’s prefilled injector technology to create fill/finish capacity in France.

Fareva and ApiJect Plan Vaccine Packaging Capacity in France 

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Isolators move into smaller-volume processes, including cell and gene therapy manufacturing.

Trends in Isolator Equipment

Hallie Forcinio is packing editor for Pharmaceutical Technology and Pharmaceutical Technology Europe, editorhal@sbcglobal.net.

New equipment meets needs for faster vial labeling and RFID for unit-level serialization.

Trends in Vial Labeling Equipment

Trends and technologies in pharmaceutical manufacturing were highlighted on the show floor and in the conference sessions on the INTERPHEX Innovation Stage.

Equipment Innovations for Pharma Manufacturing

Baxter will invest $100 million in new lyophilization equipment and an additional aseptic syringe filling line at its Halle/Westfalen (Germany) location.

Baxter Invests in its German Sterile Fill/Finish Manufacturing Facility

Global CDMO, ten23 health, has acquired filling technology and drug product manufacturing expert, swissfillon, enhancing its integrated offering.

ten23 health Acquires swissfillon to Enhance its Integrated Offering

In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.

Manufacturing, Parenterals and Injectables